BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

PLoS By Category | Recent PLoS Articles
Chemistry - Critical Care and Emergency Medicine - Molecular Biology - Nephrology - Physiology

Novel Retinoic Acid Receptor Alpha Agonists for Treatment of Kidney Disease
Published: Friday, November 18, 2011
Author: Yifei Zhong et al.

by Yifei Zhong, Yingwei Wu, Ruijie Liu, Zhengzhe Li, Yibang Chen, Todd Evans, Peter Chuang, Bhaskar Das, John Cijiang He

Development of pharmacologic agents that protect podocytes from injury is a critical strategy for the treatment of kidney glomerular diseases. Retinoic acid reduces proteinuria and glomerulosclerosis in multiple animal models of kidney diseases. However, clinical studies are limited because of significant side effects of retinoic acid. Animal studies suggest that all trans retinoic acid (ATRA) attenuates proteinuria by protecting podocytes from injury. The physiological actions of ATRA are mediated by binding to all three isoforms of the nuclear retinoic acid receptors (RARs): RARa, RARß, and RAR?. We have previously shown that ATRA exerts its renal protective effects mainly through the agonism of RARa. Here, we designed and synthesized a novel boron-containing derivative of the RARa-specific agonist Am580. This new derivative, BD4, binds to RARa receptor specifically and is predicted to have less toxicity based on its structure. We confirmed experimentally that BD4 binds to RARa with a higher affinity and exhibits less cellular toxicity than Am580 and ATRA. BD4 induces the expression of podocyte differentiation markers (synaptopodin, nephrin, and WT-1) in cultured podocytes. Finally, we confirmed that BD4 reduces proteinuria and improves kidney injury in HIV-1 transgenic mice, a model for HIV-associated nephropathy (HIVAN). Mice treated with BD4 did not develop any obvious toxicity or side effect. Our data suggest that BD4 is a novel RARa agonist, which could be used as a potential therapy for patients with kidney disease such as HIVAN.